Immunocore Ltd of Oxford, UK has secured its third partnership with a major pharmaceutical company relating to the exploitation of its recombinant T-cell receptor technology platform – this time with MedImmune, the biologics unit of AstraZeneca Plc. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
